Drug-induced kidney disease - Pathology and current concepts

Annals of the Academy of Medicine Singapore

Volumn 38, Issue 3, 2009, Pages 240-250

  Loh, Alwin H L ^a   Cohen, Arthur H ^b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug; Kidney; Nephrotoxicity; Pathology

Indexed keywords

BEVACIZUMAB; CAPTOPRIL; CHLOROQUINE; CHLORPROMAZINE; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DIETHYLENE GLYCOL; HYDRALAZINE; INFLIXIMAB; INTERFERON; ISONIAZID; LITHIUM; METHYLDOPA; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PENICILLAMINE; PROCAINAMIDE; PROPYLTHIOURACIL; QUINIDINE; RAPAMYCIN; SODIUM DIHYDROGEN PHOSPHATE;

ANALGESIC NEPHROPATHY; CLINICAL FEATURE; GLOMERULAR STRUCTURE; GLOMERULONEPHRITIS; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX NEPHRITIS; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY STRUCTURE; KIDNEY TUBULE DISORDER; PODOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 64549156901     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 2007;49:A6-7, S1-296.
2. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003;83:253-307.
3. Andrews PM, Porter KR. A scanning electron microscopic study of the nephron. Am J Anat 1974;140:81-115.
4. Andrews P. Morphological alterations of the glomerular (visceral) epithelium in response to pathological and experimental situations. J Electron Microsc Tech 1988;9:115-44.
5. Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 2001;10:543-9.
6. Barisoni L, Mundel P. Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol 2003;23:353-60.
7. Akhtar M, Al Mana H. Molecular basis of proteinuria. Adv Anat Pathol 2004;11:304-9.
8. Lahdenkari AT, Lounatmaa K, Patrakka J, Holmberg C, Wartiovaara J, Kestila M, et al. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol 2004;15:2611-8.
9. van den Berg JG, van den Bergh Weerman MA, Assmann KJ, Weening JJ, Florquin S. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004;66:1901-6.
10. Finkelstein A, Fraley DS, Stachura I, Feldman HA, Gandy DR, Bourke E. Fenoprofen nephropathy: lipoid nephrosis and interstitial nephritis. A possible T-lymphocyte disorder. Am J Med 1982;72:81-7.
11. Warren GV, Korbet SM, Schwartz MM, Lewis EJ. Minimal change glomerulopathy associated with nonsteroidal antiinflammatory drugs. Am J Kidney Dis 1989;13:127-30.
12. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant 2003;18:245-8.
13. Alper AB Jr, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002;40:1086-90.
14. Nakao K, Sugiyama H, Makino E, Matsuura H, Ohmoto A, Sugimoto T, et al. Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma. Nephron 2002;90:498-500.
15. Dizer U, Beker CM, Yavuz I, Ortatatli M, Ozguven V, Pahsa A. Minimal change disease in a patient receiving IFN-alpha therapy for chronic hepatitis C virus infection. J Interferon Cytokine Res 2003;23:51-4.
16. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004;65:634-41.
17. Palmer BF, Henrich WL. Toxic nephropathy. In: Brenner BM, editor. Brenner and Rector's The Kidney. WB Saunders, 2004:1625-58.
18. Rabb H, Colvin RB. Case records of the Massachusetts General Hospital. Case 31-2007. A 41-year-old man with abdominal pain and elevated serum creatinine. N Engl J Med 2007;357:1531-41.
19. Dunn M. Are COX-2 selective inhibitors nephrotoxic? Am J Kidney Dis 2000;35:976-77.
20. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;43:368-82.
21. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-72.
22. Markowitz GS, Fine PL, D'agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002;39:1118-22.
23. Desikan R, Veksler Y, Raza S, Stokes B, Sabir T, Li ZJ, Jagannath S. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002;119:496-9.
24. Detwiler RK, Falk RJ, Hogan SL, Jennette JC. Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994;45:1416-24.
25. Valeri A, Barisoni L, Appel GB, Seigle R, D'Agati V. Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int 1996;50:1734-46.
26. Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999;56:2203-13.
27. Bariety J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A. Podocytes undergo phenotypic changes and express macrophagic- associated markers in idiopathic collapsing glomerulopathy. Kidney Int 1998;53:918-25.
28. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999;10:51-61.
29. Sharif K, Goyal M, Kershaw D, Kunkel R, Wiggins R. Podocyte phenotypes as defined by expression and distribution of GLEPP1 in the developing glomerulus and in nephrotic glomeruli from MCD, CNF, and FSGS. A dedifferentiation hypothesis for the nephrotic syndrome.
30. Exp Nephrol 1998;6:234-44.
31. Ohtaka A, Ootaka T, Sato H, Soma J, Sato T, Saito T, et al. Significance of early phenotypic change of glomerular podocytes detected by Pax2 in primary focal segmental glomerulosclerosis. Am J Kidney Dis 2002;39:475-85.
32. Shankland SJ. Cell cycle regulatory proteins in glomerular disease. Kidney Int 1999;56:1208-15.
33. Grcevska L, Polenakovik M. Collapsing glomerulopathy: clinical characteristics and follow-up. Am J Kidney Dis 1999;33:652-7.
34. Bremer CT, Lastrapes A, Alper AB Jr, Mudad R. Interferon-alpha- induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature. Am J Clin Oncol 2003;26:262-4.
35. Fisher ME, Rossini M, Simmons E, Harris RC, Moeckel G, Zent R. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy. Am J Kidney Dis 2004;44:567-73.
36. Alves Couto C, Costa Faria L, Dias Ribeiro D, de Paula Farah K, de Melo Couto OF, de Abreu Ferrari TC. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C. Liver Int 2006;26:1294-7.
37. Rich SA. Human lupus inclusions and interferon. Science 1981;213:772-5.
38. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D'Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000;11:1439-48.
39. Schreiner A, Waldherr R, Rohmeiss P, Hewer W. Focal segmental glomerulosclerosis and lithium treatment. Am J Psychiatry 2000;157:834.
40. Muller-Hocker J, Schmid H, Weiss M, Dendorfer U, Braun GS. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature. Hum Pathol 2003;34:285-9.
41. Albay D, Adler SG, Philipose J, Calescibetta CC, Romansky SG, Cohen AH. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol 2005;18:733-8.
42. Bracamonte ER, Kowalewska J, Starr J, Gitomer J, Alpers CE. Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis 2006;48:844-50.
43. Stauber WT, Hedge AM, Trout JJ, Schottelius BA. Inhibition oflysosomal function in red and white skeletal muscles by chloroquine. Exp Neurol 1981;71:295-306.
44. Fredman P, Klinghardt GW, Svennerholm L. Effect of chloroquine on the activity of some lysosomal enzymes involved in ganglioside degradation. Biochim Biophys Acta 1987;917:1-8.
45. Radford MG Jr, Holley KE, Grande JP, Larson TS, Wagoner RD, Donadio JV, et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996;276:466-9.
46. Sugimoto T, Aoyama M, Kikuchi K, Sakaguchi M, Deji N, Uzu T, et al. Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med 2007; 46:1055-8.
47. Tubbs RR, Gephardt GN, McMahon JT, Pohl MC, Vidt DG, Barenberg SA, et al. Membranous glomerulonephritis associated with industrial mercury exposure. Study of pathogenetic mechanisms. Am J Clin Pathol 1982;77:409-13.
48. Oliveira DB, Foster G, Savill J, Syme PD, Taylor A. Membranous nephropathy caused by mercury-containing skin lightening cream. Postgrad Med J 1987;63: 303-4.
49. Aymaz S, Gross O, Krakamp B, Ortmann M, Dienes HP, Weber M. Membranous nephropathy from exposure to mercury in the fluorescent- tube-recycling industry. Nephrol Dial Transplant 2001;16:2253-5.
50. Does captopril cause renal damage in hypertensive patients? Report from the Captopril Collaborative Study Group. Lancet 1982;1:988-90.
51. Textor SC, Gephardt GN, Bravo EL, Tarazi RC, Fouad FM, Tubbs R, et al. Membranous glomerulopathy associated with captopril therapy. Am J Med 1983;74:705-12.
52. Phan L, Coulomb F, Boudon M, Gallois H, Kleinknecht D. Extramembranous glomerulonephritis induced by lithium. Nephrologie 1991;12:185-7.
53. Tam VK, Green J, Schwieger J, Cohen AH. Nephrotic syndrome and renal insufficiency associated with lithium therapy. Am J Kidney Dis 1996;27:715-20.
54. Breysse P, Couser WG, Alpers CE, Nelson K, Gaur L, Johnson RJ. Membranous nephropathy and formaldehyde exposure. Ann Intern Med 1994;120:396-7.
55. Bar-Khayim Y, Teplitz C, Garella S, Chazan JA. Trimethadione (Tridione)-induced nephrotic syndrome. A report of a case with unique ultrastructural renal pathology. Am J Med 1973;54:272-80.
56. Izzedine H, Brocheriou I, Becart J, Deray G. Probenecid-induced membranous nephropathy. Nephrol Dial Transplant 2007;22:2405-6.
57. Lindell A, Denneberg T, Enestrom S, Fich C, Skogh T. Membranous glomerulonephritis induced by 2-mercaptopropionylglycine (2-MPG). Clin Nephrol 1990;34:108-15.
58. Katz WA, Blodgett RC, Pietrusko RG. Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med 1984;101:176.
59. Francis KL, Jenis EH, Jensen GE, Calcagno PL. Gold-associated nephropathy. Arch Pathol Lab Med 1984;108:234.
60. Bacon PA, Tribe CR, Mackenzie JC, Verrier-Jones J, Cumming RH, Amer B. Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. Q J Med 1976;45:661-84.
61. Controlled trial of D(-)penicillamine in severe rheumatoid arthritis. Lancet 1973;1:275-80.
62. Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 2002;39:706-12.
63. Wooley PH, Griffin J, Panayi GS, Batchelor JR, Welsh KI, Gibson TJ. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D- penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980;303:300-2.
64. Ntoso KA, Tomaszewski JE, Jimenez SA, Neilson EG. Penicillamine- induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature. Am J Kidney Dis 1986;8:159-63.
65. Hess E. Drug-related lupus. N Engl J Med 1988;318:1460-2.
66. Hess EV. Drug-related lupus. Curr Opin Rheumatol 1991;3:809-14.
67. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, et al. Development of glomerulonephritis during anti-TNF- alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005;20:1400-6.
68. Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol 2007;27:261-4.
69. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000;43:405-13.
70. Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 2005;7:R1072-81.
71. Yu F, Chen M, Gao Y, Wang SX, Zou WZ, Zhao MH, et al. Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am J Kidney Dis 2007;49:607-14.
72. Colvin RB, Nickeleit V. Renal transplant pathology. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's Pathology of the Kidney. LWW 2007;1427-39.
73. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988;33:590-600.
74. Mason J, Muller-Schweinitzer E, Dupont M, Casellas D, Mihatsch M, Moore L, et al. Cyclosporine and the renin-angiotensin system. Kidney Int Suppl 1991;32:S28-32.
75. Lassila M. Interaction of cyclosporine A and the renin-angiotensin system; new perspectives. Curr Drug Metab 2002;3:61-71.
76. Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF- antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177-8.
77. Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 2007;3:287-93.
78. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998;140:947-59.
79. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-16.
80. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004;65:2003-17.
81. Strem EH, Epper R, Mihatsch MJ. Ciclosporin-associated arteriolopathy: the renin producing vascular smooth muscle cells are more sensitive to ciclosporin toxicity. Clin Nephrol 1995;43:226-31.
82. Mihatsch MJ, Morozumi K, Strem EH, Ryffel B, Gudat F, Thiel G. Renal transplant morphology after long-term therapy with cyclosporine. Transplant Proc 1995;27:39-42.
83. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-23.
84. Sis B, Dadras F, Khoshjou F, Cockfield S, Mihatsch MJ, Solez K. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. Am J Transplant 2006;6:1444-50.
85. Thoenes W, John HD. Endotheliotropic (hemolytic) nephroangiopathy and its various manifestation forms (thrombotic microangiopathy, primary malignant nephrosclerosis, hemolytic-uremic syndrome). Klin Wochenschr 1980;58:173-84.
86. Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, Vereerstraeten P, et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992;339:777-8.
87. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003;42:1058-68.
88. Volcy J, Nzerue CM, Oderinde A, Hewan-Iowe K. Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura. Am J Kidney Dis 2000;35:E3.
89. Balaguer F, Fernandez J, Lozano M, Miquel R, Mas A. Cocaine- induced acute hepatitis and thrombotic microangiopathy. JAMA 2005;293:797-8.
90. Wiik A. Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res Ther 2005;7:191-2.
91. Shih DJ, Korbet SM, Rydel JJ, Schwartz MM. Renal vasculitis associated with ciprofloxacin. Am J Kidney Dis 1995;26:516-9.
92. Gaffey CM, Chun B, Harvey JC, Manz HJ. Phenytoin-induced systemic granulomatous vasculitis. Arch Pathol Lab Med 1986;110:131-5.
93. Galpin JE, Shinaberger JH, Stanley TM, Blumenkrantz MJ, Bayer AS, Friedman GS, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978;65:756-65.
94. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2004;19:8-11.
95. Ruffing KA, Hoppes P, Blend D, Cugino A, Jarjoura D, Whittier FC. Eosinophils in urine revisited. Clin Nephrol 1994;41:163-6.
96. Mihatsch MJ, Knusli C. Phenacetin abuse and malignant tumors. An autopsy study covering 25 years (1953-1977). Klin Wochenschr 1982;60:1339-49.
97. Kurth T, Glynn RJ, Walker AM, Rexrode KM, Buring JE, Stampfer MJ, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003;42:234-44.
98. Walker RG. Lithium nephrotoxicity. Kidney Int Suppl 1993;42:S93-8.
99. Christensen BM, Marples D, Kim YH, Wang W, Frekiaer J, Nielsen S. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 2004;286:C952-64.
100. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-91.
101. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2008;342:1686-92.
102. Depierreux M, Van Damme B, Vanden Houte K, Vanherweghem JL. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 1994;24:172-80.
103. DiScala VA, Mautner W, Cohen JA, Levitt MF, Churg J, Yunis SL. Tubular alterations produced by osmotic diuresis with mannitol. Ann Intern Med 1965;63:767-75.
104. Morgan TO, Little JM, Evans WA. Renal failure associated with low- molecular-weight dextran infusion. Br Med J 1966;2:737-9.
105. Haas M, Sonnenday CJ, Cicone JS, Rabb H, Montgomery RA. Isometric tubular epithelial vacuolization in renal allograft biopsy specimens of patients receiving low-dose intravenous immunoglobulin for a positive crossmatch. Transplantation 2004;78:549-56.
106. Mihatsch MJ, Thiel G, Ryffel B. Cyclosporine nephrotoxicity. Adv Nephrol Necker Hosp 1988;17:303-20.
107. Heyman SN, Brezis M, Reubinoff CA, Greenfeld Z, Lechene C, Epstein FH, Rosen S. Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988;82:401-12.
108. Vogelzang NJ. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Williston Park) 1991;5:97-102.
109. Houghton DC, Campbell-Boswell MV, Bennett WM, Porter GA, Brooks RE. Myeloid bodies in the renal tubules of humans: relationship to gentamicin therapy. Clin Nephrol 1978;10:140-5.
110. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9.
111. Nasr SH, Kashtanova Y, Levchuk V, Markowitz GS. Secondary oxalosis due to excess vitamin C intake. Kidney Int 2006;70:1672.
112. Finn, LS, Berstein J. Renal disease caused by familial metabolic and hematologic diseases. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's Pathology of the Kidney. LWW, 2007:1229-30.
113. de Sequera P, Albalate M, Hernandez J, Vazquez A, Abad J, Ramiro E, et al. Acute renal failure due to sulphadiazine crystalluria in AIDS patients. Postgrad Med J 1996;72:557-8.
114. Berns JS, Cohen RM, Silverman M, Turner J. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997;30:558-60.
115. Daudon M, Estepa L, Viard JP, Joly D, Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 19973;349: 1294-5.
116. Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988;84:1067-71.
117. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sanchez de la Rosa R, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006;50:3824-32.
118. Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med 2003;349:1006-7.
119. Markowitz GS, Nasr SH, Klein P, Anderson H, Stack JI, Alterman L, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004;35:675-84.
120. Markowitz GS, Radhakrishnan J, D'Agati VD. Towards the incidence of acute phosphate nephropathy. J Am Soc Nephrol 2007;18:3020-2.
121. Hurst FP, Bohen EM, Osgard EM, Oliver DK, Das NP, Gao SW et al. Association of oral sodium phosphate purgative use with acute kidney injury. J Am Soc Nephrol 2007;18:3192-8.
122. Brunelli SM, Lewis JD, Gupta M, Latif SM, Weiner MG, Feldman HI. Risk of kidney injury following oral phosphosoda bowel preparations. J Am Soc Nephrol 2007;18:3199-205.